References
- 1. Akbarzadeh S., Ghasemi S., Kalantarhormozi M., et al.: Relationship among plasma adipokines, insulin and androgens level, as well as biochemical glycemic and lipidemic markers with incidence of PCOS in woman with normal BMI. Gynecol. Endocrinol., 28, 7, 2012.
- 2. Alcelik A., Tosun M., Ozlu M. F., et al.: Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press. Res., 35, 6, 2012.
- 3. Bastard J., Maachi M., Lagathu C. et al.: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw., 17, 1, 2006.
- 4. Bluher M.: Adipose Tissue Dysfunction in Obesity. Exp. Clin. Endocrinol. Diabetes, 117, 6, 2009.
- 5. Bremer A. A., Jialal I.: Adipose tissue dysfunction in nascent metabolic syndrome. J. Obes., ID 393192, 2013. (Epub)
- 6. Calle E. E., Thun M. J.: Obesity and cancer. Oncogene, 23, 38, 2004.
- 7. Choi J. H., Rhee E. J., Kim K. H., et al.: Plasma omentin-1 levels are reduced in non-obese woman with normal glucose tolerance and polycystic ovary syndrome. Eur. J. Endocrinol., 165, 5, 2011.
- 8. Couillard C., Ruel G., Archer W. R., et al.: Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocrinol. Metab., 90, 12, 2005.
- 9. De Pergola G., Silvestris F.: Obesity as a major risk for cancer. J. Obes., 2013:291546, 2013. (Epub)
- 10. De Souza Batista C. M., Yang R. Z., Lee M. J. et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 6, 2007.
- 11. Fazeli M. S., Dashti H., Akbarzadeh S., et al.: Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine, 62, 1, 2013.
- 12. Flehmig G., Scholz M., Kloting N. et al.: Identification of Adipokine Clusters Related to Parameters of Fat Mass, Insulin Sensitivity and Inflammation. PLoS One, 9, 6, 2014.
- 13. Hotamisligil G.S.: Inflammation and metabolic disorders. Nature, 444 (860-867), 2006.
- 14. Katsi V., Vamvakou G., Lekakis J., et al.: Omentin, Fat and Heart: Classical Music with New Instruments. Heart, Lung and Circulation, 23, 9, 2014.
- 15. Kloting N., Fasshauer M., Dietrich A. et al.: Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab., 299, 3, 2010.
- 16. Lehr S., Hartwig S., Sell H.: Adipokines: a treasure trove for discovery of biomarkers for metabolic disorders. Proteomics Clin. Appl., 6, 1-2, 2012.
- 17. Liu R., Wang X., Bu P.: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res. Clin. Pract., 93, 1, 2011.
- 18. Luque-Ramirez M., Martinez-Garcia M. A., Montes-Nieto R., et al.: Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum. Reprod., 28, 7, 2013.
- 19. Mahde A., Shaker M., Al-Mashhadani Z. Study of omentin-1 and other adipokines and hormones in PCOS patient. OMJ, 24, 2, 2009.
- 20. Moreno-Navarrete J. M., Catalan V., Ortega F. at al.: Circulating omentin concentration increases after weight loss. Nutr. Metab., 7, 27, 2010.
- 21. Moreno-Navarrete J. M., Ortega F., Castro A. et al.: Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity, 19, 8, 2011.
- 22. Oświęcimska J., Suwała A., Świętochowska E. et al.: Serum omentin levels in adolescent girls with anorexia nervosa and obesity. Physiol. Res., 2015. (Epub)
- 23. Otake S., Takeda H., Fujishima S., et al.: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J. Gastroenterol., 16, 10, 2010.
- 24. Pan H. Y., Guo L., Li Q.: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res. Clin. Pract., 88, 1, 2010.
- 25. Ridker P. M., Buring J. E., Cook N. R., et al.: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation, 107, 3, 2003.
- 26. Schaffler A., Neumeier M., Herfarth H., et al.: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta, 1732, 1-3, 2005.
- 27. Schaffler A., Zeitoun M., Wobser H. et al.: Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in humangene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel disease. Cardiovasc. Diabetol., 6, 3, 2007.
- 28. Senolt L., Polanska M., Filkova M. et al.: Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann. Rheum. Dis., 69, doi:10.1136/ ard.2009.119735, 2010.
- 29. Shetty G. K., Economides P. A., Horton E. S. at al.: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 27, 10, 2004.
- 30. Tan B. K., Adya R., Farhatullah S. et al.: Omentin-1, a novel adipokine, is decreased in overweight insulin resistant woman with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes, 57, 4, 2008.
- 31. Tan B. K., Adya R., Farhatullah S., et al.: Metformin treatment may increase omentin-1 levels in woman with polycystic ovary syndrome. Diabetes, 59, 12, 2010.
- 32. Tan B. K., Adya R., Randeva H. S.: Omentin: A Novel Link Between Inflammation, Diabesity, and Cardiovascular Disease. TCM, 20, 5, 2010.
- 33. Tan B. K., Pua S., Syed F., et al.: Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet. Med., 25, 10, 2008.
- 34. Thanyasiri P., Celermajer D. S., Adams M. R., et al.: Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease. Am. J. Physiol. Heart Circ. Physiol., 289, 2, 2005.
- 35. Tonjes A., Fasshauer M., Kratzsch J. et al.: Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes. PLoS One, 5, 11, 2010.
- 36. Uyeturk U., Sarici H., Tekce B. K. et al.: Serum omentin level in patients with prostate cancer. Med. Oncol., 31, 4, 2014.
- 37. Van Gall L. F., Mertens I. L., de Block C. E.: Mechanisms linking obesity with cardiovascular disease. Nature, 444 (875-880), 2006.
- 38. Vu A., Sidhom M. S., Bredbeck B. C., et al.: Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetology & Metabolic Syndrome, 6, 4, 2014.
- 39. Wada J.: Vaspin: A novel serpin with insulin-sensitizing effects. Expert Opin. Inv. Drug, 17, 2008.
- 40. Weisberg S. P., McCann D., Desai M., et al.: Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 12, 2003.
- 41. Xu L., Zhu G. B., Wang L., et al.: Synovial fluid omentin-1 levels are inversely correlated with radiographic severity of knee osteoarthritis. J. Investing Med., 60, 3, 2012.
- 42. Yamawaki H. Tsubaki N., Mukohda M. et al.: Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem. Biophys. Res. Commun., 393, 4, 2010.
- 43. Yamawaki H.: Vascular effects of novel adipokines: focus on vascular contractility and inflammatory responses. Biol. Pharm. Bull., 34, 3, 2011.
- 44. Yan P., Liu D., Long M., et al.: Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 119, 4, 2011.
- 45. Yang R. Z., Lee M. J. Hu H. et al.: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab., 290, 6, 2006.
- 46. Zhang Y.Y., Zou L.M.: Omentin-1, new adipokine, promotes apoptosis through regulating Sirt1-dependant p53 deacetylation in hepatocellular carcinoma cells. Eur. J. Pharmacol., 698, 1-3, 2013.
- 47. Zheng L., Weng M., Qi M., et al.: Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J. Cancer Res. Clin. Oncol., 138, 1, 2012.
- 48. Zhong X., Li X., Liu F., et al.: Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NK-κB pathway. Biochem. Biophys. Res. Commun., 425, 2, 2012.
- 49. Zhong X., Zhang H., Tan H. et al.: Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica, 32, 7, 2011.